Skip to content
Home - Media - Press releases - 2002    
5 June 2002
ASTRAZENECA RECEIVES FDA 'APPROVABLE' LETTER FOR CRESTOR™

AstraZeneca today confirms that it has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for 'Crestor' (rosuvastatin). The Company is reviewing its contents, and has no further comment at this time.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $16.4 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.

Further enquires to:

AstraZeneca

Emily Denney
+44 (0)20 7304 5034

Jonathan Hunt
+44 (0)20 7304 5087

AstraZeneca websites
Search